recent
report
chlorcyclizin
ccz
overthecount
antihistamin
piperazin
drug
possess
vitro
vivo
activ
hepat
c
viru
describ
relationship
sar
effort
result
optim
novel
chlorcyclizin
deriv
antihcv
agent
sever
compound
exhibit
ec
valu
nm
hcv
infect
cytotox
select
indic
show
improv
vivo
pharmacokinet
properti
optim
molecul
serv
lead
preclin
candid
treatment
hepat
c
viru
infect
probe
studi
hepat
c
viru
pathogenesi
interact
hepat
c
viru
hcv
envelop
positivestrand
rna
viru
flavivirida
famili
hcv
replic
cycl
initi
virion
enter
host
cell
via
interact
cell
surfac
receptor
follow
phdepend
fusion
uncoat
hcv
rna
genom
translat
result
polyprotein
undergo
proteolyt
cleavag
structur
core
nonstructur
protein
rna
replic
hcv
undergo
assembl
matur
secret
process
hcv
lead
acut
chronic
inflammatori
hepat
infect
often
progress
toward
chronic
liver
diseas
includ
cirrhosi
elev
risk
develop
hepatocellular
carcinoma
vaccin
hcv
date
besid
around
million
peopl
chronic
infect
worldwid
hcv
standard
care
mani
year
limit
interferon
combin
ribavirin
rbv
combin
therapi
partial
effect
seriou
advers
effect
drug
discoveri
effort
past
year
led
new
paradigm
hcv
treatment
mark
recent
approv
multipl
directact
antivir
daa
interferonfre
regimen
daa
inhibit
certain
replic
step
hcv
replic
cycl
directli
target
viral
protein
proteas
polymeras
viral
rebound
often
observ
monotherapi
daa
due
select
drugresist
viral
mutant
thu
clinic
applic
daa
mostli
limit
combin
regimen
face
challeng
includ
addit
side
effect
complex
administr
interact
sofosbuvir
daa
approv
interferonfre
regimen
cost
typic
cours
treatment
alon
rais
concern
afford
daa
order
global
impact
burden
hcv
diseas
hosttarget
agent
hta
howev
inhibit
host
factor
essenti
viral
replic
cycl
promis
hostfactor
target
hta
includ
entri
factor
compon
viral
replic
complex
cyclophilin
bind
viral
rna
facilit
replic
higher
genet
barrier
develop
resist
hta
moreov
hta
also
use
chemic
probe
elucid
antihcv
mechan
viru
interact
howev
hta
candid
antihcv
drug
discoveri
pipelin
possibl
due
natur
primari
drug
screen
assay
mostli
base
certain
viral
protein
hcv
replicon
overal
still
need
improv
current
therapeut
regimen
explor
novel
antihcv
target
small
molecul
recent
report
antihcv
activ
chlorcyclizin
ccz
discov
screen
ncgc
pharmaceut
collect
npc
cellbas
antihcv
quantit
highthroughput
screen
qht
platform
hit
compound
chlorcylizin
hcl
ccz
figur
show
potent
vitro
antihcv
activ
prefer
liver
distribut
mous
model
well
vivo
efficaci
hcv
infect
albupascid
chimer
mous
model
engraft
primari
human
hepatocyt
ccz
also
report
chamounemanuelli
et
al
block
hcv
entri
possibl
via
cholesteroldepend
pathway
howev
target
precis
mechan
action
ccz
inhibit
hcv
entri
remain
unknown
present
sar
studi
aim
optim
ccz
antihcv
applic
focus
follow
featur
gener
nonchir
lead
improv
antihcv
potenc
modul
physicochem
properti
potenti
reduc
cn
exposur
reduct
elimin
antihistamin
activ
improv
pharmacokinet
properti
result
lead
compound
seri
repres
nonchir
compound
exhibit
increas
antihcv
activ
select
respect
improv
vivo
pharmacokinet
properti
optim
lead
compound
merit
preclin
develop
treatment
hepat
c
synthesi
ccz
analogu
display
scheme
scheme
show
synthesi
asymmetr
ccz
deriv
thu
follow
modifi
literatur
procedur
correspond
aldehyd
keton
underw
reduct
amin
commerci
avail
chiral
r
nabh
cn
presenc
acet
acid
compound
ptoluenesulfon
acid
compound
use
alcohol
solvent
afford
correspond
nalkyl
deriv
ti
oipr
requir
carri
reduct
amin
cyclopentyl
cyclohexyl
deriv
acyl
acetyl
chlorid
afford
nacyl
deriv
deuter
deriv
r
synthes
r
cd
presenc
aqueou
naoh
likewis
trifluorin
deriv
r
prepar
common
chiral
start
materi
trifluoroethyl
triflat
presenc
k
co
scheme
display
synthesi
racem
ccz
analogu
solubil
polyethylen
glycol
side
chain
start
commerci
avail
hydroxyzin
introduct
phthalimido
moieti
via
standard
mitsunobu
condit
afford
subsequ
hydrazin
mediat
deprotect
afford
primari
amin
elong
solubil
side
chain
obtain
alkyl
produc
nboc
deriv
deprotect
free
amin
subsequ
acyl
afford
scheme
synthesi
achir
dichlorcyclizin
deriv
display
scheme
start
dichlorobenzophenon
nabh
mediat
reduct
keton
follow
chlorin
socl
afford
chlorid
use
alkyl
varieti
cyclic
amin
deriv
follow
modifi
literatur
procedur
yield
compound
scheme
piperazin
deriv
alkyl
follow
modifi
literatur
procedur
produc
diehtylen
glycolcontain
compound
elong
pentaethylen
glycol
amin
probe
halogen
effect
cyclizin
scaffold
compound
prepar
accord
scheme
via
reduct
amin
acetaldehyd
correspond
piperazin
presenc
nabh
cn
acet
acid
methanol
cyclizin
scaffold
modif
via
exchang
central
tertiari
carbon
nitrogen
analogu
display
scheme
methyl
piperidon
underw
reduct
amin
correspond
anilin
afford
intermedi
amin
subsequ
underw
naryl
buchwald
condit
afford
amin
last
modif
studi
introduct
rigid
cyclizin
scaffold
display
scheme
accomplish
start
commerci
bromofluorenon
reduc
alcohol
nabh
subsequ
convert
chlorid
cacl
concentr
hcl
chlorid
use
alkyl
nethyl
piperazin
afford
cyclizin
rigid
analogu
scheme
tabl
disclos
activ
synthes
compound
structuralchem
modif
studi
center
around
ccz
antihcv
activ
report
ec
valu
concentr
compound
inhibit
viral
level
comparison
dmso
control
use
hcvluc
hcv
strain
genotyp
insert
luciferas
report
gene
infect
assay
cytotox
measur
cc
valu
concentr
compound
exhibit
cytotox
comparison
dmso
control
evalu
atplit
assay
cell
cell
line
use
measur
antivir
activ
thu
activ
hit
compound
racem
ccz
enantiom
r
confirm
good
select
select
indic
tabl
norccz
compound
known
vivo
metabolit
ccz
show
compar
antihcv
activ
reduc
select
tabl
note
interest
norccz
lack
antihistamin
activ
tabl
tabl
address
effect
two
type
structur
modif
chiral
configur
side
chain
piperazin
ring
enantiom
compound
tabl
articl
investig
effect
length
aliphat
chain
antihcv
activ
number
carbon
less
analogu
show
compar
activ
rang
low
doubledigit
nanomolar
compar
select
ccz
regardless
whether
chain
linear
branch
chain
carbon
number
led
decreas
activ
shown
compound
surprisingli
compound
cyclopentyl
ring
exhibit
improv
activ
ec
nm
compound
cyclohexyl
ring
show
activ
expect
rang
ec
nm
compar
compound
addit
acetyl
piperazin
ring
dramat
reduc
potenc
analogu
doubledigit
micromolar
valu
introduct
bulki
substitut
benzyl
group
also
reduc
antihcv
activ
compound
ec
nm
deuterium
introduc
side
chain
compound
aim
increas
metabol
impact
antihcv
activ
inde
led
slightli
improv
valu
h
r
comparison
h
r
rat
microsom
stabil
assay
moreov
trifluoromethyl
group
compound
led
complet
loss
activ
potenti
indic
pk
valu
tertiari
amin
import
antihcv
activ
side
effect
ccz
includ
drowsi
dizzi
headach
attribut
abil
cross
barrier
cn
penetr
reason
first
gener
antihistamin
drug
replac
analogu
like
cetirizin
reduc
cnsrelat
side
effect
order
explor
possibl
reduc
cn
penetr
molecul
expand
synthet
effort
introduc
oligoethylen
glycol
side
chain
structur
tabl
structur
modif
substitu
piperazin
ring
ec
sem
n
hcvluc
infect
assay
cc
sem
n
atplit
cytotox
assay
select
index
cc
ec
articl
modif
would
increas
molecular
weight
solubl
total
polar
surfac
area
number
free
rotat
bond
also
potenti
lead
toward
longer
pharmacokinet
halfliv
use
ethylen
glycol
polyethylen
glycol
linker
explor
effect
introduc
seri
function
group
termin
posit
compound
termin
carboxyl
acid
complet
lost
antihcv
activ
potenti
due
lack
cell
permeabl
moder
activ
rang
tripledigit
nanomolar
singledigit
micromolar
observ
carboxamidesubstitut
compound
tabl
compound
hydroxyl
amino
group
chain
termin
posit
display
high
antihcv
activ
moder
cytotox
noteworthi
increas
activ
retain
select
observ
compound
ec
valu
nm
select
indic
tabl
tabl
show
activ
analogu
explor
differ
phenyl
ring
substitu
thu
elimin
parachloro
substitu
reduc
activ
doubledigit
nanomolar
compound
ec
nm
singledigit
micromolar
compound
ec
introduct
addit
paracloro
substitu
ring
slightli
increas
activ
compound
ec
nm
follow
similar
trend
nonchir
dichloro
compound
also
show
increas
activ
comparison
correspond
monochloro
analogu
gener
introduct
br
substitu
led
compar
activ
select
correspond
cl
substitut
compound
shown
structur
modif
piperazin
core
display
tabl
compound
includ
comparison
compound
one
tabl
structur
modif
phenyl
ring
ec
sem
n
hcvluc
infect
assay
cc
sem
n
atplit
cytotox
assay
select
index
cc
ec
carbon
extens
piperazin
ring
retain
activ
led
increas
cytotox
replac
piperazin
ring
ring
structur
compound
led
dramat
loss
activ
contrast
compound
retain
antihcv
activ
select
compound
rigid
cyclizin
scaffold
show
ec
valu
indic
conform
ring
import
antihcv
activ
sar
studi
select
number
lead
compound
base
antihcv
activ
select
structur
divers
expand
character
tabl
cytotox
molecul
evalu
cell
primari
human
hepatocyt
compound
show
less
differ
cc
valu
two
cell
type
comparison
cell
use
antihcv
activ
assay
except
compound
less
cytotox
cell
approxim
higher
cc
tabl
antagonist
activ
chosen
compound
evalu
measur
capac
block
intern
signal
induc
histamin
numer
valu
observ
correspond
percentag
activ
induc
histamin
nm
presenc
nm
compound
use
ccz
posit
neg
control
respect
shown
tabl
result
ccz
consist
previous
report
result
lead
compound
r
h
compound
show
low
inhibit
approxim
meanwhil
r
et
medium
oligoethylen
glycol
chain
inhibitori
effect
gener
lower
ccz
compound
show
approxim
lower
inhibit
compound
long
oligoethylen
glycol
chain
show
lower
inhibitori
effect
toward
addit
hcv
replic
cycl
assay
carri
studi
target
stage
ccz
analogu
hcv
replic
cycl
lead
compound
exhibit
potent
inhibit
hcv
singlecycl
assay
singleround
infecti
hcv
hcvsc
infect
hepatocyt
assembl
new
virion
tabl
activ
suggest
ccz
analogu
inhibit
earli
step
hcv
replic
cycl
prior
assembl
analogu
test
hcv
pseudoparticl
hcvpp
assay
hcv
subgenom
replicon
assay
detect
whether
compound
target
hcvpp
entri
hcv
replic
respect
hcvpp
assay
appli
defect
retrovir
particl
harbor
hcv
envelop
glycoprotein
assess
viral
entri
inhibit
signific
inhibitori
effect
observ
hcvpp
genotyp
assay
lead
compound
except
possibl
due
cytotox
tabl
address
viral
specif
entri
process
vesicular
stomat
viru
g
pseudoparticl
vsvgpp
murin
leukemia
viru
pseudoparticl
mlvpp
test
control
inhibitori
effect
detect
tabl
worth
note
lack
hcvpp
inhibit
compound
necessarili
exclud
viru
entri
mode
action
compound
could
target
entri
step
otherwis
captur
hcvpp
system
multipl
hcv
entri
inhibitor
report
without
hcvpp
inhibitori
effect
includ
antagonist
ezetimib
human
apolipoprotein
e
peptid
genotyp
hcv
replicon
cell
line
lead
compound
fail
reduc
replicon
activ
compar
dmso
control
tabl
structur
modif
within
piperazin
core
ec
sem
n
hcvluc
infect
assay
cc
sem
n
atplit
cytotox
assay
select
index
cc
ec
articl
indic
rna
replic
target
analogu
tabl
moreov
besid
vitro
physic
properti
chosen
lead
compound
vitro
metabol
properti
tabl
antihcv
metabol
physic
properti
profil
select
analogu
ec
sem
n
hcvluc
infect
assay
cc
sem
n
atplit
cytotox
assay
select
index
cc
ec
b
compound
test
except
compound
test
respect
avoid
potenti
cytotox
c
assay
descript
assay
address
h
histamin
receptor
inhibitori
activ
numer
valu
correspond
percentag
activ
induc
histamin
nm
presenc
nm
compound
hcvsc
assay
appli
singleround
infecti
hcv
detect
inhibit
earli
stage
prior
assembl
viru
replic
cycl
hcvpp
assay
use
hcv
pseudoparticl
determin
hcvpp
entri
inhibit
murin
leukemia
viru
pseudoparticl
mlvpp
vesicular
stomat
viru
g
pseudoparticl
vsvgpp
test
control
address
viral
specif
hcv
subgenom
replicon
assay
genotyp
hcv
replicon
cell
line
use
evalu
inhibitori
effect
hcv
rna
replic
also
evalu
use
human
mous
rat
microsom
compound
show
prefer
human
microsom
stabil
min
maintain
reason
solubl
vivo
pharmacokinet
tissu
distribut
level
compound
measur
mice
singl
dose
mgkg
intraperiton
ip
rout
tabl
halflif
liver
figur
c
preferenti
liver
distribut
also
observ
shown
liverplasma
auc
last
ratio
figur
within
h
singl
dose
mgkg
liver
concentr
compound
dramat
vitro
ec
valu
detect
potenti
hepatotox
effect
alanin
transaminas
alt
level
mous
serum
measur
figur
treat
compound
alt
level
around
ul
time
point
except
h
may
suggest
potenti
transient
mild
liver
toxic
observ
conclud
clear
correl
alt
level
liver
concentr
compound
studi
whether
mild
elev
alt
level
due
compound
vehicl
control
studi
carri
dose
vehicl
alt
level
elev
multipl
time
point
treatment
vehicl
figur
overal
conclud
clear
hepatotox
detect
treatment
compound
condit
evalu
capac
compound
potenti
impact
virus
flavivirida
famili
antivir
activ
test
dengu
viru
lead
compound
show
ec
valu
denvrvp
assay
approxim
ec
valu
hcvluc
infect
tabl
togeth
cc
valu
consist
observ
cell
infect
hcvluc
tabl
select
indic
compound
dengu
viru
furthermor
activ
submit
evalu
niaid
antivir
screen
suggest
antivir
effect
mechan
analogu
hcvspecif
besid
advanc
develop
efficaci
treatment
chronic
hcv
infect
cost
side
effect
current
approv
method
point
direct
develop
altern
approach
therapeut
interven
diseas
sens
previou
studi
disclos
vitro
vivo
antihcv
properti
chlorcyclizin
ccz
first
gener
antihistamin
compound
approv
overthecount
use
afford
establish
clinic
safeti
profil
make
ccz
attract
candid
repurpos
toward
chronic
hcv
infect
http
addit
decid
carri
structur
modif
vitro
vivo
studi
optim
seri
aim
improv
antihcv
profil
focus
chemic
modif
four
major
structur
motif
chiral
side
chain
piperazin
ring
substitu
phenyl
ring
modif
piperazin
core
summar
figur
chiral
littl
effect
antivir
activ
select
dual
parachloro
substitut
aromat
ring
led
potent
nonchir
analogu
furthermor
introduct
oligoethylen
glycol
piperazin
ring
nitrogen
improv
activ
without
compromis
select
structur
modif
piperazin
core
toler
suggest
geometri
pk
valu
import
antihcv
activ
seri
select
lead
compound
also
analyz
addit
assess
cytotox
hepatocyt
primari
human
hepatocyt
show
profil
similar
observ
cell
suggest
cytotox
evalu
cell
parallel
hcv
infect
assay
provid
good
estim
cytotox
human
hepatocyt
overal
lead
compound
tabl
exhibit
excel
antivir
activ
select
host
cell
si
one
goal
medicin
chemistri
studi
elimin
antihistamin
side
effect
ccz
achiev
lead
compound
r
h
long
ethylen
glycol
chain
compound
hcv
replic
cycl
assay
lead
compound
show
inhibitori
pattern
similar
ccz
display
dramat
inhibit
earli
stage
hcv
infect
hcvsc
assay
inhibit
hcvpp
entri
hcv
replicon
system
although
exact
mechan
articl
action
ccz
still
investig
observ
strongli
suggest
lead
compound
like
follow
mechan
action
ccz
improv
activ
select
vitro
microsom
stabil
assay
carri
evalu
potenti
metabol
stabil
lead
compound
among
compound
min
human
microsom
compound
select
vivo
pharmacokinet
mous
studi
lower
vitro
cytotox
compound
show
improv
pk
properti
comparison
ccz
name
longer
halflif
retain
high
liverplasma
ratio
besid
progress
treatment
chronic
hcv
infect
among
issu
global
afford
still
import
factor
consid
within
current
treatment
option
repurpos
overthecount
drug
ccz
may
offer
afford
treatment
chronic
hcv
infect
addit
present
chemicalstructur
modif
studi
result
optim
nonchir
welltoler
ccz
analogu
improv
antihcv
potenc
pharmacokinet
properti
abl
provid
good
coverag
liver
reason
dose
lead
compound
inhibit
hcvsc
infect
without
affect
hcvpp
entri
hcv
replic
replicon
assay
similar
find
ccz
suggest
unalt
mechan
action
lead
compound
show
overal
improv
properti
select
vivo
antihcv
efficaci
studi
potenti
preclin
drug
develop
effort
aim
move
addit
compound
seri
toward
antihcv
human
clinic
trial
experiment
section
chemistri
air
moistur
sensit
reaction
perform
posit
pressur
nitrogen
ovendri
glasswar
anhydr
solvent
dichloromethan
n
ndimethylformamid
dmf
acetonitril
methanol
triethylamin
purchas
sigmaaldrich
st
loui
mo
prepar
purif
perform
water
semiprepar
hplc
system
water
corp
milford
column
use
phenomenex
luna
c
mm
phenomenex
inc
torranc
ca
flow
rate
mlmin
mobil
phase
consist
acetonitril
water
contain
trifluoroacet
acid
gradient
acetonitril
min
use
purif
fraction
collect
trigger
uv
detect
nm
analyt
analysi
perform
agil
lcm
agil
technolog
santa
clara
ca
method
min
gradient
acetonitril
contain
trifluoroacet
acid
water
contain
trifluoroacet
acid
use
min
run
time
flow
rate
mlmin
method
min
gradient
acetonitril
contain
trifluoroacet
acid
water
contain
trifluoroacet
acid
use
min
run
time
flow
rate
mlmin
phenomenex
luna
c
column
mm
use
temperatur
puriti
determin
perform
use
agil
diod
array
detector
method
method
mass
determin
perform
use
agil
mass
spectromet
electrospray
ioniz
posit
mode
h
nmr
spectra
record
varian
mhz
spectromet
agil
technolog
santa
clara
ca
chemic
shift
report
ppm
undeuter
solvent
dmso
ppm
intern
standard
dmsod
solut
analogu
test
biolog
assay
puriti
greater
base
analyt
method
bi
methanol
solut
g
mmol
meoh
ml
treat
portion
nabh
g
mmol
reaction
mixtur
stir
min
allow
warm
room
temperatur
stir
h
reaction
quench
ice
dilut
h
extract
etoac
organ
layer
separ
dri
mgso
concentr
give
titl
compound
white
solid
g
use
without
purif
chloromethylen
bi
chlorobenzen
bi
methanol
g
mmol
dissolv
ch
cl
ml
ad
drop
dmf
follow
thionyl
chlorid
ml
mmol
result
reaction
mixtur
allow
stir
room
temperatur
min
tlc
anlysi
etoac
hex
show
complet
reaction
mixtur
concentr
reduc
pressur
afford
g
white
solid
use
without
purif
bi
methyl
piperazin
solut
mg
mmol
thf
ml
treat
piperazin
mg
mmol
follow
k
co
mg
mmol
catalyt
amount
tetrabutylammonium
iodid
mg
mmol
ad
mixtur
reaction
mixtur
reflux
h
lcm
analysi
show
complet
reaction
mixtur
concentr
redisolv
etoac
organ
layer
wash
three
time
satur
nahco
solut
dri
mgso
filter
concentr
crude
product
purifi
prepar
hplc
give
mg
tfa
salt
bi
methyl
stir
solut
g
mmol
thf
ml
ad
k
co
g
mmol
ml
mmol
catalyt
potassium
iodid
mg
mmol
reaction
heat
h
reaction
mixtur
partit
etoac
h
layer
separ
organ
phase
wash
brine
dri
mgso
filter
concentr
crude
mixtur
purifi
flash
column
chromatographi
silica
gel
gradient
meoh
ch
cl
afford
mg
freebas
oil
mix
ratio
oxal
acid
form
oxal
salt
white
powder
bi
methyl
solut
mg
mmol
thf
ml
treat
mg
mmol
follow
k
co
mg
mmol
catalyt
amount
tetrabutylammonium
iodid
mg
mmol
ad
result
reaction
mixtur
heat
h
reaction
mixtur
partit
etoac
h
layer
separ
organ
phase
wash
brine
dri
mgso
filter
concentr
crude
mixtur
purifi
flash
column
chromatographi
silica
gel
gradient
meoh
ch
cl
afford
mg
freebas
oil
mix
ratio
oxal
acid
form
oxal
salt
tertbutyl
phenyl
methyl
carbam
solut
mg
mmol
dmf
ml
treat
dispers
miner
oil
nah
mg
mmol
reaction
mixtur
stir
min
room
temperatur
min
mixtur
ad
solut
tertbutyl
ethoxi
ethyl
carbam
mg
mmol
dmf
ml
result
mixtur
allow
stir
overnight
mixtur
quench
h
extract
ch
cl
organ
layer
separ
dri
mgso
filter
concentr
crude
residu
purifi
prepar
hplc
give
mg
tfa
salt
phenyl
methyl
solut
mg
mmol
ch
cl
ml
treat
trifluoroacet
acid
ml
reaction
mixtur
stir
min
room
temperatur
min
lcm
analysi
show
complet
reaction
mixtur
concentr
crude
residu
purifi
prepar
hplc
give
mg
tfa
salt
antibiot
co
hcvluc
hcv
strain
insert
luciferas
report
gene
pseudotyp
virus
vsvgpp
produc
report
hcvluc
hcv
strain
insert
luciferas
report
gene
hcvsc
singleround
infecti
defect
hcv
particl
pseudotyp
virus
vsvgpp
produc
report
hcvluc
infect
atplit
assay
cell
plate
plate
cellswel
incub
overnight
cell
infect
hcvluc
presenc
increas
concentr
compound
interest
viral
level
measur
h
treatment
use
renilla
luciferas
assay
system
promega
madison
wi
usa
atpbas
cell
viabil
assay
carri
parallel
evalu
cytotox
atplit
assay
kit
perkinelm
waltham
usa
concentr
valu
led
viral
inhibit
cytotox
ec
cc
calcul
use
nonlinear
regress
equat
graphpad
prism
softwar
graphpad
softwar
inc
la
jolla
ca
usa
hcv
replic
cycl
assay
hcvsc
assay
cell
cultur
plate
cellswel
overnight
infect
hcvsc
presenc
compound
treatment
h
incub
viral
level
detect
luciferas
assay
hcv
subgenom
replicon
assay
hcv
replicon
gt
cell
plate
plate
cellswel
incub
overnight
cell
treat
test
compound
h
luciferas
activ
measur
hcvpp
assay
cell
seed
plate
cellswel
cultur
overnight
cell
infect
hcvpp
gt
vsvgpp
mlvpp
h
presenc
compound
treatment
cell
wash
cultur
h
follow
luciferas
assay
detect
hcv
entri
posit
control
cyclosporin
bafilomycin
nm
test
parallel
inhibit
assay
pathhunt
gpcr
assay
kit
discoverx
fremont
ca
usa
use
follow
antagonist
procedur
pathhunt
cell
plate
white
plate
clear
bottom
cultur
overnight
incub
compound
interest
h
agonist
histamin
ad
plate
incub
addit
h
chemiluminesc
signal
read
min
incub
detect
agent
room
temperatur
percent
antihistamin
activ
calcul
base
result
histaminetr
well
denvrvp
assay
niaid
screen
cell
plate
plate
cellswel
cultur
overnight
dengu
rvp
integr
molecular
philadelphia
pa
usa
ad
cell
increas
concentr
compound
interest
dengu
rvp
reproduc
measur
luciferas
signal
h
treatment
lycorin
hcl
test
posit
control
nonclin
preclin
servic
program
offer
nation
institut
allergi
infecti
diseas
niaid
http
wwwniaidnihgovlabsandresourcesresourcesdmidinvitro
pagesinvitroaspx
use
antivir
screen
virus
virus
includ
hepat
b
viru
hcv
replicon
herp
simplex
human
cytomegaloviru
vaccinia
viru
dengu
viru
influenza
viru
respiratori
syncyti
viru
sar
coronaviru
polioviru
rift
valley
fever
viru
tacarib
viru
venezuelan
equin
enceph
viru
vitro
vivo
pharmacokinet
properti
vitro
microsom
stabil
measur
incub
compound
humanmouserat
liver
microsom
presenc
cofactor
nadph
concentr
compound
measur
lcmsm
min
halflif
calcul
describ
kinet
solubl
compound
determin
phosphat
buffer
ph
use
evolut
pion
inc
wwwpioninccom
fulli
autom
system
sampl
prepar
sampl
analysi
data
process
effect
permeabl
compound
determin
via
passiv
diffus
use
stir
doublesink
pampa
parallel
artifici
membran
permeabl
assay
method
pion
inc
wwwpioninccom
fulli
autom
system
sampl
prepar
sampl
analysi
data
process
vivo
pharmacokinet
male
mice
g
obtain
charl
river
laboratori
wilmington
mice
hous
central
anim
facil
nih
bethesda
md
h
cycl
hous
temperatur
rel
humid
control
respect
anim
free
access
water
food
experiment
procedur
approv
anim
care
use
committe
nih
dose
concentr
mgml
appropri
compound
freshli
prepar
water
pharmacokinet
evalu
singl
intraperiton
administr
mgkg
blood
liver
sampl
collect
predos
h
three
sampl
n
collect
time
point
concentr
compound
plasma
liver
determin
ultraperform
liquid
spectrometri
analysi
uplcmsm
pharmacokinet
paramet
calcul
use
noncompartment
method
model
pharmacokinet
softwar
packag
phoenix
winnonlin
version
certara
st
loui
mo
usa
area
plasma
liver
concentr
versu
time
curv
auc
calcul
use
linear
trapezoid
method
warrant
slope
appar
termin
phase
estim
log
linear
regress
use
least
data
point
termin
rate
constant
deriv
slope
auc
estim
sum
auc
time
last
measur
concentr
c
appar
termin
halflif
calcul
